{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:57:01Z","timestamp":1793451421738,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.phrs.2022.106362","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T02:13:45Z","timestamp":1658456025000},"page":"106362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders"],"prefix":"10.1016","volume":"183","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106362_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib3","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106362_bib4","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106362_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2022.106362_bib6","series-title":"Harrison\u2019s Principles of Internal Medicine","first-page":"2671","article-title":"Introduction to the immune system","author":"Haynes","year":"2022"},{"key":"10.1016\/j.phrs.2022.106362_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J."},{"issue":"17","key":"10.1016\/j.phrs.2022.106362_bib8","first-page":"395","article-title":"STATs: An old story, yet mesmerizing","volume":"l","author":"Abroun","year":"2015","journal-title":"Cell J."},{"key":"10.1016\/j.phrs.2022.106362_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","article-title":"Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA","volume":"93","author":"Chen","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106362_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"issue":"409","key":"10.1016\/j.phrs.2022.106362_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35053086","article-title":"CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling","volume":"18","author":"Irie-Sasaki","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106362_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106362_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106362_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2022.106362_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2022.106362_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.phrs.2022.106362_bib19","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1021\/bi036109b","article-title":"Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state","volume":"43","author":"Chatti","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2022.106362_bib20","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106362_bib21","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106362_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2022.106362_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib38","series-title":"Reference module in life sciences","first-page":"1","article-title":"Src Family Tyrosine Kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2022.106362_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2022.106362_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2022.106362_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106362_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammar\u00e9n","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2022.106362_bib51","author":"Recio","year":"2019","journal-title":"JAK, oncokinase Hematol. Cancer"},{"key":"10.1016\/j.phrs.2022.106362_bib52","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106362_bib53","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2015.132142","article-title":"JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications","volume":"100","author":"Springuel","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2022.106362_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.821344","article-title":"JAK\/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies","volume":"13","author":"Rah","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2022.106362_bib55","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.phrs.2022.106362_bib56","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med Chem. Commun."},{"key":"10.1016\/j.phrs.2022.106362_bib58","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2022.106362_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"issue":"D1","key":"10.1016\/j.phrs.2022.106362_bib60","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2022.106362_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib63","first-page":"gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","author":"Kanev","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.phrs.2022.106362_bib64","doi-asserted-by":"crossref","first-page":"pii: E908","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2022.106362_bib65","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106362_bib66","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.3390\/molecules25153321","article-title":"Inside perspective of the synthetic and computational toolbox of JAK Inhibitors: recent updates","volume":"25","author":"Coricello","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2022.106362_bib67","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106362_bib68","first-page":"2281","article-title":"Baricitinib is first approved covid-19 immunomodulatory treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2022.106362_bib69","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106362_bib70","first-page":"1","article-title":"Management of myeloproliferative neoplasms in the molecular era: from research to practice","volume":"42","author":"Pettit","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.phrs.2022.106362_bib71","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2022.106362_bib72","first-page":"75","article-title":"Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.phrs.2022.106362_bib73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/DDDT.S287218","article-title":"The effectiveness of ruxolitinib for acute\/chronic graft-versus-host disease in children: a retrospective study","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2022.106362_bib74","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.820586","article-title":"the safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.phrs.2022.106362_bib76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/1744666X.2022.2038134","article-title":"Tofacitinib for the treatment of active ankylosing spondylitis in adults","volume":"18","author":"Mohanakrishnan","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2022.106362_bib77","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2022.106362_bib78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.phrs.2022.106362_bib79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/1744666X.2022.2060822","article-title":"The suitability of treating atopic dermatitis with Janus kinase inhibitors","volume":"18","author":"Narla","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2022.106362_bib80","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2147\/DDDT.S340459","article-title":"Evaluating upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: design, development, and potential position in therapy","volume":"16","author":"Napolitano","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.phrs.2022.106362_bib81","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2022.106362_bib82","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib83","article-title":"Janus Kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib","volume":"11","author":"Nogueira","year":"2021","journal-title":"Dermatol. Pr. Concept"},{"key":"10.1016\/j.phrs.2022.106362_bib84","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2022.106362_bib85","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/vaccines10060951","article-title":"The AI-assisted identification and clinical efficacy of baricitinib in the treatment of COVID-19","volume":"10","author":"Richardson","year":"2022","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.phrs.2022.106362_bib86","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","article-title":"Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6","volume":"400","author":"Chrencik","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2022.106362_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2022.106362_bib91","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.phrs.2022.106362_bib92","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2022.106362_bib93","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib94","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2022.106362_bib95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2022.106362_bib96","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib97","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2022.106362_bib98","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \u201cdrug-like\u201d properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib99","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2022.106362_bib100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Compout Sci."},{"key":"10.1016\/j.phrs.2022.106362_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106362_bib105","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib106","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Disco Today"},{"key":"10.1016\/j.phrs.2022.106362_bib107","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib108","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2022.106362_bib109","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2022.106362_bib110","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2022.106362_bib111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The jakinibs in systemic lupus erythematosus: progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.phrs.2022.106362_bib112","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/jm9012906","article-title":"Selective p38\u03b1 inhibitors clinically evaluated for the treatment of chronic inflammatory disorders","volume":"53","author":"Goldstein","year":"2010","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2022.106362_bib113","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tips.2005.12.002","article-title":"Targeting Rho and Rho-kinase in the treatment of cardiovascular disease","volume":"27","author":"Budzyn","year":"2006","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2022.106362_bib114","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.3390\/ijms22169098","article-title":"GSK-3\u03b2, FYN, and DYRK1A: master regulators in neurodegenerative pathways","volume":"22","author":"Demuro","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106362_bib115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/biom11030354","article-title":"PERK pathway and neurodegenerative disease: to inhibit or to activate?","volume":"11","author":"Shacham","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2022.106362_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2020.100769","article-title":"The complexities of PKC\u03b1 signaling in cancer","volume":"80","author":"Black","year":"2021","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.phrs.2022.106362_bib117","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.job.2019.07.002","article-title":"Regulation of osteoclast function via Rho-Pkn3-c-Src pathways","volume":"61","author":"Uehara","year":"2019","journal-title":"J. Oral. Biosci."},{"key":"10.1016\/j.phrs.2022.106362_bib118","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:13Z","timestamp":1760913373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822003073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":118,"alternative-id":["S1043661822003073"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106362","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106362"}}